A detailed review of the outbreak of COVID-19
© 2021 The Author(s). Published by BRI..
The disease COVID-19 caused by SARS-CoV-2 is the third highly infectious human Coronavirus epidemic in the 21st century due to its high transmission rate and quick evolution of its pathogenicity. Genomic studies indicate that it is zoonotic from bats. The COVID-19 has led to significant loss of lives and a tremendous economic decline in the world. Generally, the population at risk of a fatal outcome are the elderly and those who are debilitated or are immune compromised. The fatality rate is high, but now is reduced after the development of preventive vaccine although an effective treatment by drug against the virus is yet to be developed. The treatment is narrowed to the use of several anti-viral drugs, or other re-purposed drugs. Social distancing, therefore, has emerged as a putative method to decrease the rate of infection. In this review, we summarize the aspects of the disease that is so far have come to light and review the impact of the infection on our society, healthcare, economy, education, and environment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Frontiers in bioscience (Landmark edition) - 26(2021), 6 vom: 30. Mai, Seite 149-170 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Das, Kabita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 19.07.2021 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.52586/4931 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327093099 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327093099 | ||
| 003 | DE-627 | ||
| 005 | 20231225200019.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.52586/4931 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327093099 | ||
| 035 | |a (NLM)34162043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Das, Kabita |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A detailed review of the outbreak of COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Author(s). Published by BRI. | ||
| 520 | |a The disease COVID-19 caused by SARS-CoV-2 is the third highly infectious human Coronavirus epidemic in the 21st century due to its high transmission rate and quick evolution of its pathogenicity. Genomic studies indicate that it is zoonotic from bats. The COVID-19 has led to significant loss of lives and a tremendous economic decline in the world. Generally, the population at risk of a fatal outcome are the elderly and those who are debilitated or are immune compromised. The fatality rate is high, but now is reduced after the development of preventive vaccine although an effective treatment by drug against the virus is yet to be developed. The treatment is narrowed to the use of several anti-viral drugs, or other re-purposed drugs. Social distancing, therefore, has emerged as a putative method to decrease the rate of infection. In this review, we summarize the aspects of the disease that is so far have come to light and review the impact of the infection on our society, healthcare, economy, education, and environment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Phronetic needs for COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Socio-economic impacts | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Vaccine development | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Pingali, M Shivapriya |e verfasserin |4 aut | |
| 700 | 1 | |a Paital, Biswaranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Falguni |e verfasserin |4 aut | |
| 700 | 1 | |a Pati, Samar Gourav |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Anirudh |e verfasserin |4 aut | |
| 700 | 1 | |a Varadwaj, Pritish Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Samanta, Sintu Kumar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in bioscience (Landmark edition) |d 2009 |g 26(2021), 6 vom: 30. Mai, Seite 149-170 |w (DE-627)NLM186959230 |x 2768-6698 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:6 |g day:30 |g month:05 |g pages:149-170 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.52586/4931 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 6 |b 30 |c 05 |h 149-170 | ||